The homogeneity of cardiovascular clinical trial populations limits the generalizability of results and compounds health inequities faced by women, older adults and people of colour. This Comment highlights the importance of diversity in clinical trial populations and describes multifaceted interventions that might help to close the diversity gap in trial enrolment.

中文翻译：

---

增加心血管临床试验人群的代表性和多样性

心血管临床试验人群的同质性限制了结果的普遍性，并加剧了女性、老年人和有色人种面临的健康不平等。该评论强调了临床试验人群多样性的重要性，并描述了可能有助于缩小试验注册多样性差距的多方面干预措施。